Impact Therapeutics Granted CFDA Approval for China Test of PARP Inhibitor

Impact Therapeutics of Nanjing announced its IND for a PARP inhibitor, IMP4297, was approved by the CFDA. Impact believes IMP4297 has the potential to become a best-in-class drug. In February, Impact began a Australian Phase I trial of the candidate and has already treated its first patient in China as well. The company said the CFDA issued its approval only one year after the application was submitted, showing the CFDA's reforms are speeding up the regulatory process. IMP4297 is a Class 1.1 candidate that was discovered and developed in China. More details.... Share this with colleagues: // //